157 related articles for article (PubMed ID: 21978673)
1. Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41.
Jiang S; Tala SR; Lu H; Zou P; Avan I; Ibrahim TS; Abo-Dya NE; Abdelmajeid A; Debnath AK; Katritzky AR
Bioorg Med Chem Lett; 2011 Nov; 21(22):6895-8. PubMed ID: 21978673
[TBL] [Abstract][Full Text] [Related]
2. Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41.
He XY; Lu L; Qiu J; Zou P; Yu F; Jiang XK; Li L; Jiang S; Liu S; Xie L
Bioorg Med Chem; 2013 Dec; 21(23):7539-48. PubMed ID: 23673219
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41.
Jiang S; Tala SR; Lu H; Abo-Dya NE; Avan I; Gyanda K; Lu L; Katritzky AR; Debnath AK
J Med Chem; 2011 Jan; 54(2):572-9. PubMed ID: 21190369
[TBL] [Abstract][Full Text] [Related]
4. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41.
Cai L; Jiang S
ChemMedChem; 2010 Nov; 5(11):1813-24. PubMed ID: 20845360
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of 3-substituted 2,5-dimethyl-N-(3-(1H-tetrazol-5-yl)phenyl)pyrroles as novel potential HIV-1 gp41 inhibitors.
He XY; Zou P; Qiu J; Hou L; Jiang S; Liu S; Xie L
Bioorg Med Chem; 2011 Nov; 19(22):6726-34. PubMed ID: 22014749
[TBL] [Abstract][Full Text] [Related]
6. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41.
Wang Y; Lu H; Zhu Q; Jiang S; Liao Y
Bioorg Med Chem Lett; 2010 Jan; 20(1):189-92. PubMed ID: 19932616
[TBL] [Abstract][Full Text] [Related]
8. Computer-aided design, synthesis, and biological activity evaluation of potent fusion inhibitors targeting HIV-1 gp41.
Tan JJ; Zhang B; Cong XJ; Yang LF; Liu B; Kong R; Kui ZY; Wang CX; Hu LM
Med Chem; 2011 Jul; 7(4):309-16. PubMed ID: 21568877
[TBL] [Abstract][Full Text] [Related]
9. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
[TBL] [Abstract][Full Text] [Related]
10. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
[No Abstract] [Full Text] [Related]
11. Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors.
Katritzky AR; Tala SR; Lu H; Vakulenko AV; Chen QY; Sivapackiam J; Pandya K; Jiang S; Debnath AK
J Med Chem; 2009 Dec; 52(23):7631-9. PubMed ID: 19746983
[TBL] [Abstract][Full Text] [Related]
12. Development of HIV-1 fusion inhibitors targeting gp41.
Lu K; Asyifah MR; Shao F; Zhang D
Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 gp41: mediator of fusion and target for inhibition.
Weiss CD
AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
[TBL] [Abstract][Full Text] [Related]
14. Tannin inhibits HIV-1 entry by targeting gp41.
Lü L; Liu SW; Jiang SB; Wu SG
Acta Pharmacol Sin; 2004 Feb; 25(2):213-8. PubMed ID: 14769212
[TBL] [Abstract][Full Text] [Related]
15. A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure.
Pang W; Wang RR; Gao YD; Yang LM; Sun Y; Huang JF; Tien P; Zheng YT
J Biomol Screen; 2011 Feb; 16(2):221-9. PubMed ID: 21297108
[TBL] [Abstract][Full Text] [Related]
16. Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.
An T; Ouyang W; Pan W; Guo D; Li J; Li L; Chen G; Yang J; Wu S; Tien P
Antiviral Res; 2012 Jun; 94(3):276-87. PubMed ID: 22426469
[TBL] [Abstract][Full Text] [Related]
17. Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies.
Mzoughi O; Gaston F; Granados GC; Lakhdar-Ghazal F; Giralt E; Bahraoui E
ChemMedChem; 2010 Nov; 5(11):1907-18. PubMed ID: 20922745
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
Pan C; Liu S; Jiang S
J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
[TBL] [Abstract][Full Text] [Related]
19. [1,2,6-tri-O-galloyl-beta-D-glucopyranose inhibits gp41-mediated HIV envelope fusion with target cell membrane].
Sun W; Wang HT; Xia CL; Wu SG; Jiang SB; Jiang ZH; Liu SW
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul; 28(7):1127-31. PubMed ID: 18676243
[TBL] [Abstract][Full Text] [Related]
20. HIV fusion inhibitors.
Qadir MI; Malik SA
Rev Med Virol; 2010 Jan; 20(1):23-33. PubMed ID: 19827030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
